Investor Presentation First Nine Months of 2022
40
Investor presentation First nine months of 2022
The total branded diabetes market has a global value of DKK
~350 billion annually
DKK
billion
Global diabetes market
DKK
The USA
billion
+14%
400
+14%
2021/2022 2020/2021 Growth at CER
200
164
346
136
150
+32%
-11%
100
81
292
300
60
+2%
40 44
50
15 14
+26%
27 19
0
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
200
DKK
Outside the USA
billion
+14%
-4%
+37%
200
182
111 112
116
156
0%
+35%
150
0%
100
84
63
55 53
100
70 69
+46%
0%
43
35
40 39
+44%
36
50
24
24
0
Total
0
Insulin
GLP-1
DPP-4i
SGLT-2i
Total
Insulin
GLP-1
DPP-4i
SGLT-2i
Source: Company announcements as of Q2 2022; 2021/2022 data based on Q3 2021 to Q2 2022 and 2020/2021 data based on Q3 2020 to Q2 2021
Note: The segment value is based on reported figures, whilst the market growth is under constant exchange rate (CER). For Novo Nordisk the diabetes growth includes Insulin and GLP-1, excluding 'other Diabetes care'.
Novo NordiskⓇView entire presentation